Biosimilar Labeling: Sandoz Makes Good-For-The-Goose Defense
This article was originally published in The Pink Sheet Daily
Executive Summary
Defending Zarxio against AbbVie citizen petition, Novartis subsidiary says analytical data aren’t needed in biosimilar product labeling to inform prescribing decision.